On the stock market since 2019, it operates in the world of health and science. It has 4,035 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades 47% below its peak. The market has trimmed its expectations for the company.
The company sells $4.6B a year; the problem isn’t sales — it’s costs running above that number.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
A loss of $86M against $4.6B in annual sales.
At the current pace of spending, the cash lasts about 2.1 years. After that, the company needs to find new money.
On our five-subject report card, CVET sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CVET has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.